Form 8-K

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: July 21, 2004

BioCryst Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)


Delaware
(State or other jurisdiction
of incorporation) 		000-23186
(Commission
File Number) 		62-1413174
(IRS Employer
Identification #)

2190 Parkway Lake Drive, Birmingham, Alabama 35244
(Address of Principal Executive Office)

(205) 444-4600
(Registrant’s telephone number, including area code)



Item 7.   Exhibits.

  Exhibit No. Description  
  99.1 Press release dated July 21, 2004 entitled “BioCryst Reports Second
Quarter 2004 Financial Results”		  

Item 12.   Results of Operations and Financial Condition:

        On July 21, 2004, the Company issued a news release announcing its financial results for the quarter ended June 30, 2004. A copy of the news release is furnished as exhibit 99.1 hereto and is incorporated by reference into Item 12 of Form 8-K.



SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: July 21, 2004 BioCryst Pharmaceuticals, Inc.


By:  /s/ Michael A. Darwin
        ———————————————
        Michael A. Darwin
        Chief Financial Officer and Chief
        Accounting Officer



EXHIBIT INDEX


  Item Description  
  99.1 Press release dated July 21, 2004 entitled “BioCryst Reports Second Quarter 2004 Financial Results”